Skip to main content

Table 1 Patient and healthy control characteristics at baseline

From: Neurofilament levels, disease activity and brain volume during follow-up in multiple sclerosis

Clinical and laboratory data Patients
n = 41
Healthy controls
n = 22
p value
Women/men (% women) 32/9 (78%) 17/5 (77%) 0.9
Agea (years) 31 (24–36) 32 (26–41) 0.3
Diagnosis (CIS/RRMS) 19/22 N/A  
Relapse within last 2 months (yes/no) 23/18 N/A  
Mean disease durationb (months) 11.8 N/A  
Median disease durationb (months) 3.5 N/A  
Disease durationb (number of subjects)   N/A  
 0–1 months 10   
 1.25–2 months 7   
 2.25–3 months 3   
 3.25–6 months 6   
 6.5–12 months 7   
 13–24 months 3   
 25–36 months 2   
 37–48 months 1   
 49–120 months 2   
Median EDSS 2.0 N/A  
EDSS (number of subjects)
 0 6 22  
 1.0 12   
 1.5 2   
 2.0 12   
 2.5 3   
 3.0 1   
 3.5 2   
 4.0 2   
 4.5 1   
CSF mononuclear cell counta 4.6 × 106/L (1.8–9.2) 2.1 × 106/L (0.9–2.7) 0.001
Albumin ratioa 4.8 (3.4–6.0) 4.7 (3.6–5.3) 0.5
IgG indexa 0.7 (0.5–1.1) 0.5 (0.5–0.5) < 0.001
IgG synthesis indexa 1.3 (1.0–2.1) 0.9 (0.9–1.0) < 0.001
Oligoclonal CSF IgG bands (pos/neg) 33/8 0/22 < 0.001
  1. p values from chi-square test for sex distribution and oligoclonal bands and from Mann-Whitney U test for age and CSF data
  2. N/A not applicable, DMT disease-modifying treatment
  3. aMedian and within brackets interquartile range
  4. bDisease duration refers to time from first symptom suggestive of demyelinating disease